特应性皮炎生物标志物整合模型凸显疾病的系统性特征
该研究在25例中重度特应性皮炎(AD)患者中,于基线和环孢素A治疗后检测皮损、非皮损皮肤及血液的生物标志物,用单变量和多变量方法分析与SCORAD及增生评分的相关性;结果显示血清细胞因子和趋化因子升高且随治疗下降,非皮损模型相关性最强,整合血清标志物后进一步改善。
要点
- AD存在系统性免疫激活,血清IL-13、IL-22、CCL17升高且治疗后可降低。
- SCORAD与非皮损皮肤标志物的相关性比皮损更强。
- 多变量整合模型可改善生物标志物与SCORAD及增生评分的相关性。
核心结论
- AD不仅是表皮异常,还涉及系统性免疫激活,整合皮损、非皮损和血清标志物的模型能更好地反映疾病严重程度。
研究设计与样本
- 在25例中重度AD患者中,于基线和环孢素A治疗后检测皮损、非皮损皮肤及血液的生物标志物,并与SCORAD和增生评分进行单变量及多变量相关性分析。
主要发现
- 与健康个体相比,AD患者血清细胞因子和趋化因子(IL-13、IL-22、CCL17)升高,且治疗后降低。
- SCORAD与皮损及非皮损皮肤的免疫指标(IL-13、IL-22)和表皮指标(厚度、K16)相关,在非皮损中相关性更强。
- 血清细胞因子在基线和治疗时与非皮损标志物的相关性更高。
- 多变量U统计量改善了基线和治疗反应时与SCORAD的相关性。
- 非皮损模型相关性最强,整合血清标志物后进一步改善;生物标志物与增生评分的相关性更好。
临床怎么用
- 临床评估AD严重程度时,可关注非皮损皮肤和血清生物标志物所反映的系统性炎症。
- 血清IL-13、IL-22、CCL17等指标可能有助于监测治疗反应,但需进一步验证。
局限性
- 样本量较小(25例),结论为初步数据,需要更大队列确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current atopic dermatitis (AD) models link epidermal abnormalities in lesional skin to cytokine activation. However, there is evolving evidence of systemic immune activation and detectable abnormalities in nonlesional skin. Because some of the best single correlations with severity (Scoring of AD, or SCORAD) are detected not only in lesional but also nonlesional skin and blood, more complex biomarker models of AD are needed. We thus performed extensive biomarker measures in these compartments using univariate and multivariate approaches to correlate disease biomarkers with SCORAD and with a combined hyperplasia score [thickness and keratin 16 (K16) mRNA] at baseline and after cyclosporine A treatment in 25 moderate to severe AD patients. Increases in serum cytokines and chemokines (IL-13, IL-22, CCL17) were found in AD versus healthy individuals and were reduced with treatment. SCORAD correlated with immune (IL-13, IL-22) and epidermal (thickness, K16) measures in lesional and, even more strongly, in nonlesional AD. Serum cytokines also had higher correlations with nonlesional markers at baseline and with treatment. Multivariate U statistics improved baseline and treatment-response SCORAD correlations. Nonlesional models showed the strongest correlations, with further improvement upon integration of serum markers. Even better correlations were obtained between biomarkers and the hyperplasia score. Larger cohorts are needed to confirm these preliminary data.
引用
- Ungar B, Garcet S, Gonzalez J, et al. An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease. J Invest Dermatol. 2016. PMID: 27825969. doi:10.1016/j.jid.2016.09.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。